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N. Pusterla, P.H. Kass, S. Mapes, C. Wademan, N. Akana, C. Barnett, C. MacKenzie, and W. Vaala
Background: Recent surveillance studies for equine respiratory viruses have shown that equine influenza virus (EIV) con-
tinues to be a prevalent respiratory virus of equids throughout the United States and Europe.
Objectives: To gain a better understanding of the prevalence and epidemiology of EIV shed by horses, mules and donkeys
in the United States from March 2010 to November 2013.
Animals: 2,605 equids.
Methods: Nasal secretions from index cases with acute onset of respiratory disease were tested by qPCR for EIV. Multi-
level logistic regression was used to model the association between EIV status and prevalence factors. Furthermore, observa-
tions from EIV-positive study horses were compared to previous data from March 2008 to February 2010.
Results: A total of 230 (9.7%) index cases tested qPCR positive for EIV. A higher-than-expected proportion of EIV
qPCR-positive horses occurred in the 1–5, 6–10, and 11–15 age groups when compared to the <1 year of age group. Fever,
nasal discharge and coughing were positively associated with EIV-positive horses. EIV qPCR-positive study cases were signif-
icantly older and more often vaccinated against EIV compared to EIV qPCR-positive animals from the 2008-2010 study
period.
Conclusions and Clinical Importance: This study provides valuable and contemporary information on the frequency of
EIV detected by qPCR in the United States. The results also underscore that older and previously vaccinated horses were
susceptible to EIV.
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Equine influenza virus (EIV) is considered one of theleading causes of infectious respiratory diseases in
equids worldwide.1–3 Because of the highly contagious
nature and rapid spread of EIV, this virus has severe
financial implications for the horse industry.4 The glo-
bal transportation of horses has been responsible for
numerous outbreaks of EIV by introduction of the virus
into previously unexposed horse populations.5,6 Adher-
ence to strict quarantine and vaccination protocols and
vigilant monitoring are required to avoid the introduc-
tion and spread of EIV among all horse populations.
Two distinct subtypes of influenza virus have been iso-
lated from horses since 1956.7 These are represented by
the following prototype strains: influenza A/equine/Pra-
gue/56 (H7N7) and influenza A/equine/Miami/63
(H3N8). EIV diverged into the Eurasian and American
lineages in the late 1980s, with the American lineage
diverging further into the Kentucky, South American,
and Florida sublineages.8 Recent EIV surveillance data
showed that Florida sublineage viruses from both clades
1 and 2 circulate in Europe, whereas only clade 1
viruses have been reported from North America.1,9–11
Although the circulating EIV strains generally cause
sporadic disease mainly in unvaccinated horses, recent
surveillance data from the OIE (Office International des
Epizooties) documented lack of vaccine efficacy against
Florida sublineage viruses from both clades 1 and 2.9 A
previous study by the authors on the prevalence and
epidemiology of important viral and bacterial respira-
tory pathogens associated with upper respiratory tract
diseases showed that EHV-4 and EIV were the 2 most
commonly detected respiratory viruses in horses in the
United States.12 The same study documented that EIV-
positive cases were reported with increased frequency
during the winter through spring months, in all
ages with increased frequency in 1–5-year-old horses,
and in all breeds and uses. Furthermore, among the 60
EIV qPCR-positive cases reported in that study, nasal
discharge, fever and coughing were the most commonly
reported clinical signs. The objective of this study was
to gain a better understanding of the prevalence and
epidemiology of EIV shed by horses presented to veteri-
narians with upper respiratory tract infections from
March 2010 to November 2013 and to compare cate-
gorical observations from EIV-positive horses from
March 2010 to November 2013 to previous data from
March 2008 to February 2010.
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Materials and Methods
Animals and Collection of Samples
Veterinarians in 239 equine veterinary practices located in 38
states and previously enrolled in a voluntary surveillance program
for equine respiratory pathogens were asked to collect nasal
secretions from horses with signs of acute upper respiratory tract
infection (Fig. 1). The case definition of horses to be sampled
included unexplained fever (T > 101.5°F) and ≥1 of the following
signs: lethargy, nasal discharge and coughing. Case submission
occurred over a 45-month period (March 2010 to November 2013).
A diagnosis of EIV infection was made based on the presence of
clinical signs and laboratory detection of EIV by qPCR as previ-
ously described.12
A questionnaire was used to collect information pertaining to
the patient and its clinical signs. The questionnaire included signal-
ment (age, breed, and sex), use (racing, show, pleasure, breeding,
and others), vaccination history (date of vaccination and type of
vaccine used), and presence of clinical signs at the time of sample
collection (general attitude, appetite, rectal temperature, nasal dis-
charge, ocular discharge, presence of cough, and distal limb
edema). Information pertaining to vaccine brand and manufac-
turer was not requested.
The study veterinarians collected nasal secretions using two 6
inch rayon-tipped swabs.a Recommendations were given to collect
nasal secretions from the nostrils with the most obvious discharge.
After collection of nasal secretions, both swabs were placed in a
15 mL conical tube containing 2 mL of viral transport medium
(minimal essential medium with 0.125% gentamicin and 0.1%
amphotericin B). Samples were kept refrigerated and shipped on
ice overnight to the laboratory at the University of California,
School of Veterinary Medicine, Davis.
Nucleic acid extraction from nasal secretions was performed the
day of sample arrival to the laboratory using an automated nucleic
acid extraction systemb according to the manufacturer’s recom-
mendations. Total RNA was purified from nasal secretions and
transcribed to complementary DNA as previously described.12
Nasal secretions were assayed for the presence of the HA1 gene of
EIV using a previously reported qPCR assay.12 To determine the
sample quality and efficiency of nucleic acid extraction, all samples
were assessed for the presence of the housekeeping gene eGAPDH
as previously described.13
Statistical Analysis
Multilevel logistic regression was used to model the association
between EIV status and prevalence factors. State and clinic were
used in the hierarchical model as nested random effects, whereas
prevalence factors were treated as fixed effects. Factors were indi-
vidually analyzed, and those with P ≤ .05 were included in a mul-
tivariable model. Results are reported as prevalence odds ratios
and 95% confidence intervals. Furthermore, categorical observa-
tions from 230 EIV qPCR-positive horses from March 2010 to
November 2013 were compared to previous data from March 2008
to February 2010 (60 EIV qPCR positives).12 For all statistical
analyses, values of P ≤ .05 were considered significant.
Results
A total of 230 (9.7%) index cases tested qPCR posi-
tive for EIV. The ages of the affected horses ranged
from 3 weeks to 24 years (median, 6 years; Table 1).
The breeds of affected animals included Quarter Horse
(107), Thoroughbred (20), Warmblood (19), American
Paint Horse (16), Pony breed (15), Arabian (12), Stan-
dardbred (4), Draft Horse breed (4), others (20) and
not reported (13). There were 89 mares or fillies, 20
stallions or colts, 105 geldings, and 16 animals with no
reported sex. The actual or intended use for the
affected animals was pleasure riding (84), show (74),
racing (21), breeding (7), others (22), and not reported
Fig 1. Geographic location of equine veterinary clinics enrolled in the voluntary surveillance program for equine respiratory pathogens.
Blue pins represent veterinary clinics which submitted nasal secretions from horses negative for EIV by qPCR. Red dots represent veteri-
nary clinics which submitted nasal secretions from horses positive for EIV by qPCR. The location of the laboratory which performed all
the molecular analysis is marked with a yellow circle.
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Table 1. Signalment, use, vaccination history, clinical signs, and qPCR results for EIV in horses participating in a
voluntary surveillance program for equine infectious respiratory pathogens from March 2010 to November 2013 and
from March 2008 to February 2010.
Control study population
2010–2013 (2,375)
EIV qPCR
positive (230)
Control study population
2008–2010 (761)
EIV qPCR
positive (60)
Age (years)
<1 154 (6.5%) 3 (1.3%) 130 (17.1%) 5 (8.3%)
1–5 768 (32.3%) 104 (45.2%) 255 (33.5%) 37 (61.7%)
6–10 562 (23.7%) 80 (34.8%) 142 (18.7%) 13 (21.6%)
11–15 369 (15.5%) 25 (10.9%) 105 (13.8%) 3 (5.0%)
16–20 184 (7.7%) 3 (1.3%) 42 (5.5%) 1 (1.7%)
>20 123 (5.2%) 2 (0.9%) 21 (2.7%) 0
Not reported 215 (9.1%) 13 (5.6%) 66 (8.7%) 1 (1.7%)
Breed
Thoroughbred 287 (12.1%) 20 (8.7%) 160 (21.0%) 2 (3.3%)
Quarter Horse 842 (35.4%) 107 (46.5%) 144 (18.9%) 25 (41.7%)
Warmblood 256 (10.8%) 19 (8.3%) 89 (11.7%) 0
American Paint 151 (6.4%) 16 (7.0%) 46 (6.0%) 9 (15.0%)
Pony 102 (4.3%) 15 (6.5%) 38 (5.0%) 2 (3.3%)
Arabian 164 (6.9%) 12 (5.2%) 29 (3.8%) 1 (1.7%)
Standardbred 43 (1.8%) 4 (1.7%) 14 (2%) 0
Spanish 0 0 9 (1.2%) 0
Draft 29 (1.2%) 4 (1.7%) 9 (1.2%) 0
Mule/donkey 5 (0.2%) 0 4 (0.5%) 1 (1.7%)
Others 301 (12.7%) 20 (8.7%) 119 (15.6%) 14 (23.3%)
Not reported 195 (8.2%) 13 (5.7%) 100 (13.1%) 6 (10.0%)
Gender
Mare/filly 846 (35.6%) 89 (38.7%) 257 (33.8%) 20 (33.3%)
Gelding 1035 (43.6%) 105 (45.6%) 300 (39.4%) 23 (38.4%)
Stallion/colt 338 (14.2%) 20 (8.7%) 140 (18.4%) 12 (20.0%)
Not Reported 156 (6.6%) 16 (7.0%) 64 (8.4%) 5 (8.3%)
Use
Show 661 (27.8%) 74 (32.2%) 242 (31.8%) 19 (31.6%)
Pleasure 891 (37.5%) 84 (36.5%) 210 (27.6%) 24 (40.0%)
Racing 200 (8.4%) 21 (9.1%) 152 (20%) 6 (10.0%)
Breeding 110 (4.6%) 7 (3.0%) 23 (3.0%) 1 (1.7%)
Others 191 (8.1%) 22 (9.6%) 56 (7.4%) 4 (6.7%)
Not reported 322 (13.6%) 22 (9.6%) 78 (10.2%) 6 (10.0%)
Vaccination
EHV-1/-4/EIV yes 855 (36.0%) 84 (36.5%) 300 (39.4%) 9 (15.0%)
EHV-1/-4/EIV no 232 (9.8%) 15 (6.5%) 103 (13.5%) 10 (16.7%)
EHV-1/-4/EIV unknown 1288 (54.2%) 131 (57.0%) 358 (47.1%) 41 (68.3%)
Clinical signs
Depression yes 1363 (57.4%) 143 (62.2%) 390 (51.3%) 34 (56.7%)
Depression no 892 (37.6%) 78 (33.9%) 320 (42.0%) 21 (35.0%)
Depression unknown 120 (5.0%) 9 (3.9%) 51 (6.7%) 5 (8.3%)
Anorexia yes 1076 (45.3%) 114 (49.6%) 327 (43.0%) 29 (48.4%)
Anorexia no 1173 (49.4%) 107 (46.5%) 384 (50.5%) 26 (43.3%)
Anorexia unknown 126 (5.3%) 9 (3.9%) 50 (6.5%) 5 (8.3%)
Fever yes 1297 (54.6%) 151 (65.6%) 426 (56%) 37 (61.6%)
Fever no 720 (30.3%) 43 (18.7%) 228 (30%) 19 (31.7%)
Fever unknown 358 (15.1%) 36 (15.7%) 107 (14%) 4 (6.7%)
Nasal discharge yes 1586 (66.8%) 214 (93.0%) 580 (76.2%) 53 (88.4%)
Nasal discharge no 686 (28.9%) 7 (3.1%) 96 (12.6%) 2 (3.3%)
Nasal discharge unknown 103 (4.3%) 9 (3.9%) 85 (11.2%) 5 (8.3%)
Ocular discharge yes 509 (21.4%) 66 (28.7%) 64 (8.4%) 12 (20.0%)
Ocular discharge no 1738 (73.2%) 155 (67.4%) 640 (84.1%) 43 (71.7%)
Ocular discharge unknown 128 (5.4%) 9 (3.9%) 57 (7.5%) 5 (8.3%)
Coughing yes 1073 (45.2%) 195 (84.8%) 345 (45.3%) 52 (86.7%)
Coughing no 1147 (48.3%) 22 (9.6%) 51 (6.7%) 3 (5.0%)
Coughing unknown 155 (6.5%) 13 (5.6%) 365 (48%) 5 (8.3%)
Limb edema yes 178 (7.5%) 5 (2.2%) 65 (8.5%) 1 (1.7%)
Limb edema no 2062 (86.8%) 213 (92.6%) 642 (84.4%) 54 (90.0%)
Limb edema unknown 135 (5.7%) 12 (5.2%) 54 (7.1%) 5 (8.3%)
Equine Influenza in the United States 419
(22). Lethargy, nasal discharge, fever and coughing
were the most commonly reported clinical signs among
affected animals. Vaccination status was unknown for
131 horses. Eighty-four horses had been vaccinated
against EIV, whereas 15 horses had never been
vaccinated.
Multivariable analysis showed significant results for
various factors, including age, breed, and specific clin-
ical signs (Table 2). Significant clustering was noted
at the clinic level (P < .001), but was negligible at the
state level. A higher-than-expected proportion of the
EIV qPCR-positive horses occurred in the 1–5, 6–10,
and 11–15 age groups when compared to the <1 year
of age group. Fewer EIV qPCR-positive horses were
found in the age groups 16–20 and >20 years of age.
No associations were found for the majority of the
breeds when compared to the most prevalent breed
(Quarter Horse breed). The prevalence odds of being
EIV positive in the “other” breed category were half
the odds in the Quarter Horse breed. Spanish breed
and the category mule or donkey were omitted from
the analysis because of the small number of animals.
The presence of fever, coughing and nasal discharge
was positively associated with EIV, whereas limb
edema was negatively associated with EIV. No signifi-
cant associations were found for use, sex, vaccination
history and specific clinical signs such as ocular dis-
charge, lethargy and anorexia.
Overall, 855 control horses had been vaccinated
against EIV. Seven-hundred-and-forty-five horses had
received a killed adjuvanted EIV vaccine and 76 horses
had received a modified-live EIV vaccine. For 34
horses, there was no record of which type of EIV vac-
cine had been administered. Time of vaccine administra-
tion to development of respiratory signs in the control
horses was <6 months for 565 horses, 6–12 months for
134 horses, >12 months for 48 horses, and not reported
for 108 horses. When evaluating the 230 EIV PCR-
postive horses, 84 had a vaccination history. Among
these horses, 69 had received a killed adjuvanted EIV
vaccine, 5 had received a modified-live EIV vaccine and
in 10 horses no EIV vaccine type was listed. For 39
EIV PCR-positive horses, the EIV vaccine had been
given <6 months before onset of respiratory signs,
between 6 and 12 months for 26 horses, >12 months for
9 horses, and for 10 horses the time from vaccine
administration was not reported. There was no statisti-
cal significance (P > .05) in the type of EIV vaccine
used (killed adjuvanted vs modified-live vaccine)
between control and EIV PCR-positive horses. Further-
more, significantly more horses in both groups (control
and EIV PCR-positive) had been vaccinated in the time
period <6 months when compared to the time period
6–12 months and >12 months (P < .01).
When both EIV qPCR-positive groups were com-
pared, several statistical differences were noticed. Horses
qPCR-positive for EIV in 2010–2013 tended to be older
than horses in the EIV 2008–2010 group (P = .001).
EIV-positive stallions and colts were more commonly
identified during the 2008–2010 period (P = .039).
Table 2. Univariable and multivariable analysis or selected demographic and clinical factors associated with EIV
qPCR status. Results are reported as prevalence odds ratios and 95% confidence intervals.
Factors
Univariable analysis Multivariable analysis
Prevalence
odds ratio
95% confidence interval
P-value
Prevalence
odds ratio
95% confidence interval
P-valueLower bound Upper bound Lower bound Upper bound
Age (years)
<1 1.00 1.00
1–5 9.46 2.85 31.33 <.001 7.37 2.16 25.11 .001
6–10 10.24 3.04 34.45 <.001 8.94 2.58 31.06 .001
11–15 4.22 1.19 14.91 .025 4.85 1.31 17.97 .018
16–20 0.91 0.17 4.77 .911 1.04 0.19 5.65 .966
>20 0.93 0.15 5.89 .936 1.31 0.20 8.70 .780
Breed
Quarter Horse 1.00 1.00
Thoroughbred 0.54 0.29 0.99 .045 0.49 0.24 1.03 .060
Warm blood 0.42 0.22 0.81 .009 1.00 0.48 2.10 .994
American Paint 0.76 0.42 1.39 .374 0.83 0.41 1.66 .597
Pony 1.16 0.59 2.27 .668 1.41 0.62 3.21 .411
Arabian 0.50 0.26 0.97 .040 0.67 0.31 1.44 .302
Standardbred 0.45 0.11 1.80 .263 0.69 0.12 3.90 .673
Draft 1.06 0.33 3.40 .916 1.98 0.41 9.63 .397
Others 0.45 0.26 0.77 .004 0.50 0.26 0.96 .038
Clinical signs
Nasal discharge 13.87 6.37 30.21 <.001 7.19 2.99 17.28 <.001
Ocular discharge 1.42 1.00 2.03 .050 1.05 0.69 1.60 .805
Coughing 10.59 6.64 16.89 <.001 7.91 4.52 13.83 <.001
Fever 2.02 1.39 2.93 <.001 2.43 1.59 3.70 <.001
Limb edema 0.26 0.10 0.66 .005 0.21 0.06 0.71 .013
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Horses qPCR-positive for EIV in 2010–2013 tended to
be vaccinated more often against EIV than the qPCR-
positive EIV horses from the 2008–2010 period
(P = .001). There were no significant differences
between the 2 EIV groups with regard to use and clini-
cal presentation.
Discussion
Recently, the OIE expert surveillance panel on EIV
reported on outbreaks of equine influenza in a variety
of countries including the United States.9 Vaccination
breakdowns were observed in Thoroughbred yearlings
in Kentucky, sport horses in France, racehorses in Ire-
land and, recently, horses imported into South Arabia
and Japan. Sequence analysis of the HA1 gene of vari-
ous EIV isolates identified clade 1 and clade 2 viruses
of the Florida sublineage with only clade 1 viruses
found in the United States. Our study results are in
agreement with the equine influenza activity reported by
the OIE and also showed that contemporary EIV cases
were reported with higher frequency in middle-aged
horses and horses previously vaccinated with EIV vac-
cines.
Although index cases represented a wide range of
ages, 62% of them were ≤10 years of age, which reflects
the higher susceptibility of young animals to infectious
respiratory pathogens.14 Equine Influenza virus in the
age group 1–5 years of age was overrepresented, similar
to a previous study.12 Also, a higher-than-expected pro-
portion of the EIV qPCR-positive horses occurred in
the 6–10 and 11–15 age groups. Although every age
group appeared to be susceptible to EIV, the age-depen-
dent susceptibility may be a nonspecific marker for dif-
ferences in management, exposure and immunity.
Equine Influenza virus infections were mainly character-
ized by fever, nasal discharge and coughing, which is in
agreement with previous studies.12,14,15
Despite a large number of submissions with unknown
vaccination history, a similar percentage of control
study horses and EIV qPCR-positive horses were vacci-
nated against EHV-1/-4 and EIV. Surprisingly, qPCR-
positive EIV cases in 2010–2013 tended to be vaccinated
more often than qPCR-positive EIV horses from the
2008–2010 period. This observation is in agreement with
the OIE expert surveillance panel on EIV and questions
the efficacy of EIV vaccines available in the United
States. The suboptimal protection of vaccines commer-
cially available in the United States also is supported by
the observation that significantly more horses in the
EIV PCR-positive group had been vaccinated in the
time period <6 months when compared to the time per-
iod 6–12 months and >12 months. Information pertain-
ing to vaccine brand and manufacturer was unavailable
for the study horses, and thus no conclusions can be
drawn regarding the efficacy of specific vaccines. Com-
mercial killed and inactivated EIV vaccines should con-
tain epidemiologically relevant viruses and should be
updated in a timely manner to confer optimal protec-
tion. The OIE expert surveillance panel on EIV recom-
mends that vaccines for the international market should
contain both clade 1 (A/eq/Ohio/2003-like) and clade 2
(A/eq/Richmond/1/2007-like) viruses of the Florida sub-
lineage.9
In conclusion, this follow-up surveillance study
focused on 2,605 horses with upper respiratory tract
infection for which epidemiological information was
collected over a 45-month period. This study provides
valuable and contemporary information on the fre-
quency of EIV detected by qPCR. The results also
point to the fact that older and previously vaccinated
horses were susceptible to EIV. This study highlights the
importance of conducting biosurveillance for respiratory
pathogens to gather epidemiological information and
determine the frequency of vaccine breakdowns.
Footnotes
a Puritan Products Company LLC, Guilford, ME
b CAS-1820 X-tractor Gene, Corbett Life Science, Australia
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